Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
AXGN Stock Summary
Top 10 Correlated ETFs
In the News
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
ALACHUA, Fla. and TAMPA, Fla., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Axogen to Participate at Upcoming Investor Conferences
ALACHUA and TAMPA, Fla., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in two investor conferences in September.
AxoGen, Inc. (AXGN) Q2 2023 Earnings Call Transcript
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Consultant Karen Zaderej - Chairman, Chief Executive Officer and President Pete Mariani - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Dave Turkaly - JMP Securities Ross Osborn - Cantor Fitzgerald Caitlin Cronin - Canaccord Genuity Chris Pasquale - Nephron Research Operator Greetings. Welcome to the AxoGen, Inc. Reports Second Quarter 2023 Financial Results Conference Call.
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
AxoGen (AXGN) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.06 per share a year ago.
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
ALACHUA, Fla. and TAMPA, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2023 financial results on Monday, August 7, 2023 after the market closes. Axogen management will host an investment-community conference call and webcast at 4:30 p.m. ET following the release.
AxoGen: Far More Constructive With Q1 Numbers, Profitability The Next Hurdle
AxoGen is showing potential for growth, and management expects a record $160 million in revenue this year. Focus on core and active accounts has yielded positive results, with YoY growth of 23% and 9% respectively. However, the lack of earnings and catalysts makes it challenging to estimate an accurate valuation, warranting a hold rating for now.
Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet
The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release.
AXGN Financial details
AXGN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||2.26||2.72||2.81||3.09||3.29|
|Net income per share||-0.6||-0.74||-0.62||-0.68||-0.65|
|Operating cash flow per share||-0.48||-0.51||-0.24||-0.33||-0.38|
|Free cash flow per share||-0.66||-3.61||-0.81||-1.01||-0.89|
|Cash per share||3.14||2.46||2.6||2.04||1.16|
|Book value per share||3.96||3.37||3.08||2.73||2.4|
|Tangible book value per share||3.93||3.33||3.03||2.66||2.31|
|Share holders equity per share||3.96||3.37||3.08||2.73||2.4|
|Interest debt per share||0.03||0.09||1.37||1.67||1.62|
|Price to sales ratio||9.04||6.58||6.37||3.03||3.03|
|EV to sales||8.75||6.27||6.42||3.3||3.41|
|Enterprise value over EBITDA||-37.32||-25.54||-36.46||-20.09||-18.82|
|EV to operating cash flow||-41.11||-33.69||-74.84||-31.4||-29.39|
|EV to free cash flow||-30.01||-4.73||-22.36||-10.07||-12.65|
|Free cash flow yield||-0.03||-0.2||-0.05||-0.11||-0.09|
|Debt to equity||0||0.03||0.44||0.6||0.67|
|Debt to assets||0||0.02||0.27||0.32||0.35|
|Net debt to EBITDA||1.23||1.24||-0.25||-1.66||-2.08|
|Sales general and administrative to revenue||0.28||0.29||0.24||0.25||0.27|
|Research and developement to revenue||0.14||0.16||0.16||0.19||0.2|
|Intangibles to total assets||0.01||0.01||0.01||0.01||0.02|
|Capex to operating cash flow||0.37||6.12||2.35||2.12||1.32|
|Capex to revenue||-0.08||-1.14||-0.2||-0.22||-0.15|
|Capex to depreciation||-7.76||-42.28||-6.53||-5.99||-4.38|
|Stock based compensation to revenue||0.09||0.1||0.08||0.09||0.11|
|Return on tangible assets||-0.14||-0.19||-0.12||-0.14||-0.14|
|Tangible asset value||145.8M||130.64M||121.1M||109.69M||97.35M|
|Net current asset value||137.76M||112.53M||67.02M||31.58M||3.69M|
|Days sales outstanding||66.62||57.96||57.26||52.04||58.43|
|Days payables outstanding||127.58||173.82||77.75||94.28||135.5|
|Days of inventory on hand||338.42||291.62||211.9||265.71||285.76|
|Capex per share||-0.18||-3.1||-0.57||-0.69||-0.51|
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
|Revenue per share||0.88||0.9||0.86||0.89||0.96|
|Net income per share||-0.09||-0.13||-0.16||-0.16||-0.1|
|Operating cash flow per share||-0.02||0.03||-0.17||0.01||0.04|
|Free cash flow per share||-0.12||-0.14||-0.28||-0.1||-0.05|
|Cash per share||1.26||1.22||0.89||0.81||0.76|
|Book value per share||2.4||2.53||2.29||2.27||2.27|
|Tangible book value per share||2.32||2.44||2.2||2.17||2.17|
|Share holders equity per share||2.4||2.53||2.29||2.27||2.27|
|Interest debt per share||1.6||1.69||1.58||1.57||1.59|
|Price to sales ratio||13.62||11.03||10.97||10.26||5.21|
|EV to sales||15.06||12.47||12.59||11.41||6.09|
|Enterprise value over EBITDA||-153||-98.67||-74.73||-71.02||-95.85|
|EV to operating cash flow||-807.84||331.14||-62.19||1.49K||154.62|
|EV to free cash flow||-106.32||-83.41||-38.54||-99.28||-110.27|
|Free cash flow yield||-0.01||-0.01||-0.03||-0.01||-0.01|
|Debt to equity||0.67||0.67||0.69||0.69||0.69|
|Debt to assets||0.35||0.35||0.35||0.35||0.35|
|Net debt to EBITDA||-14.66||-11.41||-9.61||-7.19||-13.84|
|Sales general and administrative to revenue||0.24||0.25||0.25||0.25||0.21|
|Research and developement to revenue||0.19||0.19||0.18||0.19||0.17|
|Intangibles to total assets||0.02||0.02||0.02||0.02||0.02|
|Capex to operating cash flow||6.6||-4.97||0.61||-16.02||-2.4|
|Capex to revenue||-0.12||-0.19||-0.12||-0.12||-0.09|
|Capex to depreciation||-3.57||-5.79||-3.66||-4.46||-2.77|
|Stock based compensation to revenue||0.1||0.11||0.08||0.14||0.12|
|Return on tangible assets||-0.02||-0.03||-0.04||-0.04||-0.02|
|Tangible asset value||98M||97.35M||93.66M||93.1M||93.52M|
|Net current asset value||8.38M||3.69M||-3.26M||-8.31M||-9.38M|
|Days sales outstanding||52.02||55.21||54.69||50.89||50.73|
|Days payables outstanding||0||131.37||0||0||0|
|Days of inventory on hand||278.57||277.06||266.27||264.43||257.58|
|Capex per share||-0.11||-0.17||-0.11||-0.11||-0.09|
AXGN Frequently Asked Questions
What is AxoGen, Inc. stock symbol ?
AxoGen, Inc. is a US stock , located in Alachua of Fl and trading under the symbol AXGN
What is AxoGen, Inc. stock quote today ?
AxoGen, Inc. stock price is $6.22 today.
Is AxoGen, Inc. stock public?
Yes, AxoGen, Inc. is a publicly traded company.